Brain drug targeting: a computational approach for overcoming blood-brain barrier

Drug Discovery Today

Volumn 14, Issue 21-22, 2009, Pages 1030-1036

  Mehdipour, Ahmad Reza ^a   Hamidi, Mehrdad ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE DERIVATIVE; PRODRUG;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTIFICIAL NEURAL NETWORK; BLOOD BRAIN BARRIER; BRAIN DISEASE; CAPILLARY ENDOTHELIUM; COMPUTER MODEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; HUMAN; MATHEMATICAL COMPUTING; MOLECULAR MODEL; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, MOLECULAR; PEPTIDES; PERMEABILITY; PRODRUGS;

EID: 70350397386     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.009     Document Type: Review

References (56)

1. Pardridge W.M. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol. 6 (2006) 494-500
2. Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today 12 (2007) 54-61
3. Cecchelli R., et al. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 6 (2007) 650-661
4. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr. Drug Metab. 7 (2006) 183-203
5. Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8 (2003) 927-933
6. de Boer A.G., and Gaillard P.J. Strategies to improve drug delivery across the blood-brain barrier. Clin. Pharmacokinet. 46 (2007) 553-576
7. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
8. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?. Drug Discov. Today 13 (2008) 1099-1106
9. Norinder U., and Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 54 (2002) 291-313
10. Hammarlund-Udenaes M., et al. On the rate and extent of drug delivery to the brain. Pharm. Res. 25 (2008) 1737-1750
11. van de Waterbeemd H., et al. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aid. Mol. Des. 15 (2001) 273-286
12. Wan H., et al. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J. Med. Chem. 50 (2007) 4606-4615
13. Martin I. Prediction of blood-brain barrier penetration: are we missing the point?. Drug Discov. Today 9 (2004) 161-162
14. Pardridge W.M. Log(BB), PS products and in silico models of drug brain penetration. Drug Discov. Today 9 (2004) 392-393
15. Jeffrey P., and Summerfield S.G. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37 (2007) 1135-1151
16. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23 (1980) 682-684
17. 2 receptor histamine antagonists. J. Med. Chem. 31 (1988) 656-671
18. Abraham M.H., et al. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J. Pharm. Sci. 83 (1994) 1257-1268
19. Abraham M.H., et al. Application of hydrogen bonding calculations in property based drug design. Drug Discov. Today 7 (2002) 1056-1063
20. Luco J.M. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J. Chem. Inf. Comput. Sci. 39 (1999) 396-404
21. Hughes J.D., et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18 (2008) 4872-4875
22. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88 (1999) 815-821
23. Osterberg T., and Norinder U. Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics. J. Chem. Inf. Comput. Sci. 40 (2000) 1408-1411
24. Abraham M.H. The factors that influence permeation across the blood-brain barrier. Eur. J. Med. Chem. 39 (2004) 235-240
25. Liu X., et al. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 32 (2004) 132-139
26. Bendels S., et al. In silico prediction of brain and CSF permeation of small molecules using PLS regression models. Eur. J. Med. Chem. 43 (2008) 1581-1592
27. Summerfield S.G., et al. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 316 (2006) 1282-1290
28. Goodwin J.T., and Clark D.E. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind". J. Pharmacol. Exp. Ther. 315 (2005) 477-483
29. Winkler D.A., and Burden F.R. Modelling blood-brain barrier partitioning using Bayesian neural nets. J. Mol. Graph Model. 22 (2004) 499-505
30. Hemmateenejad B. Correlation ranking procedure for factor selection in PC-ANN modeling and application to ADMETox evaluation. Chemom. Intel Lab. Syst. 75 (2004) 231-245
31. Hemmateenejad B., et al. Accurate prediction of the blood-brain partitioning of a large set of solutes using ab initio calculations and genetic neural network modeling. J. Comput. Chem. 27 11 (2006) 1125-1135
32. Zhou X.F., et al. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab. Dispos. 33 (2005) 321-328
33. Zhang H. A new nonlinear equation for the tissue/blood partition coefficients of neutral compounds. J. Pharm. Sci. 93 (2004) 1595-1604
34. Mente S.R., and Lombardo F. A recursive-partitioning model for blood-brain barrier permeation. J. Comput. Aid. Mol. Des. 19 (2005) 465-481
35. Subramanian G., and Kitchen D.B. Computational models to predict blood-brain barrier permeation and CNS activity. J. Comput. Aid. Mol. Des. 17 (2003) 643-664
36. Kortagere S., et al. New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm. Res. 25 (2008) 1836-1845
37. Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann. N. Y. Acad. Sci. 507 (1987) 289-306
38. Perioli L., et al. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. Eur. J. Med. Chem. 39 (2004) 715-727
39. Crivori P., et al. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43 (2000) 2204-2216
40. Denora N., et al. Novel l-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety. Pharm. Res. 24 (2007) 1309-1324
41. Teixido M., et al. Evolutionary combinatorial chemistry, a novel tool for SAR studies on peptide transport across the blood-brain barrier. Part 2. Design, synthesis and evaluation of a first generation of peptides. J. Pept. Sci. 11 (2005) 789-804
42. Burton P.S., et al. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85 (1996) 1336-1340
43. Kim D.C., et al. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm. Res. 10 (1993) 1710-1714
44. Chikhale E.G., et al. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm. Res. 11 (1994) 412-419
45. Conradi R.A., et al. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm. Res. 9 (1992) 435-439
46. Thomas S.A., et al. Structure-activity relationships of a series of [d-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J. Pharmacol. Exp. Ther. 281 (1997) 817-825
47. Hansen M., et al. Predicting cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (2008) 572-579
48. Hällbrink M., et al. Prediction of cell-penetrating peptides. Int. J. Pep. Res. Ther. 11 (2005) 249-259
49. Dobson P.D., and Kell D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat. Rev. Drug Discov. 7 (2008) 205-220
50. Chang C., et al. In silico strategies for modeling membrane transporter function. Drug Discov. Today 10 (2005) 663-671
51. Chang C., and Swaan P.W. Computational approaches to modeling drug transporters. Eur. J. Pharm. Sci. 27 (2006) 411-424
52. Srinivas E., et al. Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. Curr. Drug Metab. 7 (2006) 205-217
53. Chang C., et al. Pharmacophore-based discovery of ligands for drug transporters. Adv. Drug Deliv. Rev. 58 (2006) 1431-1450
54. Allen D.D., and Geldenhuys W.J. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci. 78 (2006) 1029-1033
55. Geldenhuys W.J., et al. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 14 (2004) 3085-3092
56. Geldenhuys W.J., et al. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg. Med. Chem. 13 (2005) 4253-4261